CTRI/2014/09/005075进行中（未招募）2 期
A Multi Center, Double-Blind, Randomized, Controlled Study to Determine the Safety and Pharmacokinetics of Ifetroban Injection in Hepatorenal Syndrome
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Note- There is no upper limit specified in the protocol.
- •Inclusion Criteria
- •1. Chronic liver disease, defined as cirrhosis with ascites based on clinical findings (biopsy not necessary).
- •2. Subjects with either Type 1 or Type 2 renal dysfunction defined as follows:
- •i) At least a doubling of the initial serum creatinine to >220 μmol/L
- •(2.5 mg/dL), occurring over a period of less than 2 weeks.
- •ii) A 50% or greater reduction in the initial 24-hour creatinine
- •clearance to <20 mL/min occurring over a period of less than
- •b) Type 2: defined as at least a 33% reduction in creatinine clearance
- •occurring over a period of greater than 2 weeks, with a serum creatinine
- •>133μmol/L (1.5 mg/dL).
- •3. Oliguria occurring within 48 hours prior to 1st administration CTM. Oliguria is defined as either of the following:
- •a. An average urine output of <35 mL/hr measured for at least 4 hours, occurring with a measured central venous pressure (CVP) >12 mmHg.
- •b. In the absence of CVP monitoring, oliguria that is not corrected by a fluid challenge of at least 20mL/kg isotonic crystalloid or comparable volume of colloid.
排除标准
- •1. History of allergy or hypersensitivity to ifetroban
- •2. Pregnant or nursing
- •3. Less than 18 years of age
- •4. SCr > 5.0 mg/dL
- •5. Platelet count at screening of <30 x 103 per μL
- •6. Active gastrointestinal hemorrhage
- •7. Evidence of obstructive or parenchymal renal disease (e.g., acute tubular necrosis, glomerular diseases, interstitial nephritis, and urinary obstruction, or lab results indicating proteinuria >500 mg/day, microhematuria [ >50 RBCs/high power field], and/or abnormal renal ultrasound scanning).
- •8. Current or recent (within the preceding 5 days) treatment with any of the
- •following drugs: aminoglycosides, acyclovir, cisplatin, methotrexate,
- •cyclosporine, amphotericin B.
- •9. Presence of shock defined as hypotension, with a mean arterial pressure less than 50 mmHG.
- •10. NYHA class 3 or 4 heart failure.
- •11. Presence of hepatocellular carcinoma not transplantable by Milan criteria
- •12. Cardiopulmonary arrest without full recovery of mental status
- •13. Moribund and death expected within five days
- •14. Uncontrolled bacterial or fungal infections, defined as receiving appropriate antimicrobial therapy for >24 hours
- •15. Burns >30% body surface area
- •16. Exposed to investigational drugs within 30 days before 1st CTM administration.
- •17. Inability to understand the requirements of the study. (Subjects must be willing to provide written informed consent or consent of legally recognized representative, as evidenced by signature on an informed consent document approved by an Institutional Review Board [IRB], and agree to abide by the study restrictions if the subject is incapacitated, informed consent will be sought from a legally recognized representative).
- •18. Refusal to provide written authorization for use and disclosure of protected health information.
- •19. Be otherwise unsuitable for the study, in the opinion of the Investigator.
研究者
相似试验
进行中（未招募）
1 期
M7824 with cCRT in Unresectable Stage III NSCLCnresectable Stage III Non-small Cell Lung CancerMedDRA version: 20.0Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003265-34-ESMerck KGaA350
进行中（未招募）
1 期
M7824 with cCRT in Unresectable Stage III NSCLCnresectable Stage III Non-small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003265-34-DEMerck KGaA160
进行中（未招募）
1 期
M7824 with cCRT in Unresectable Stage III NSCLCnresectable Stage III Non-small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003265-34-HUMerck KGaA160
已完成
2 期
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancerlung cancerNon-small cell lung cancerNL-OMON52935Merck20
进行中（未招募）
1 期
M7824 with cCRT in Unresectable Stage III NSCLCEUCTR2018-003265-34-BEMerck KGaA160